2346-P: Access to GLP-1 Receptor Agonists (GLP-1RA) and Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) for Type 2 Diabetes Mellitus (T2DM) by Sociodemographic Factors in a Large Integrated Health System

Introduction and Objective: GLP-1 RAs and SGLT-2i have transformed T2DM management by improving glycemic control, promoting weight loss, and reducing the risk of cardiometabolic-renal disease. This study's aim was to assess real world prescribing patterns of GLP-1 RAs and SGLT-2i within a large health care system and assess variations across sociodemographic groups. Methods: A retrospective analysis of prescribing practices of GLP-1 RAs and SGLT-2i among adults with T2DM and obesity between 2022-2025 was conducted. Using ICD-10 codes and electronic prescription information, differences in medication prescribing by race/ethnicity, gender, age, and insurance status were assessed. Results: Of patients with a diagnosis of T2DM and obesity (60,239), 42% (25,519) received at least one GLP-1 RA order. The racial/ethnic group with the lowest and highest prescribing rates were Asian and Native Hawaiian/Pacific Islander, respectively. Young adults, females, and patients on Medicaid were more likely to be prescribed than older adults, males, and patients on other insurance types. SGLT-2i rates followed similar patterns. Conclusion: Young adults, women, and those on Medicaid had the highest rates of GLP-1 RA/SGLT-2i prescriptions. There is relatively consistent prescribing among racial/ethnic groups except in the Asian population. These findings should be further explored. Disclosure N. Dillard: None. S. Robinson: Research Support; Current; Lilly. K. Hays: None. H. Husby: None. M. Weinberg: None. D. Kerr: Stock/Shareholder; Current; Glooko, Inc. Research Support; Current; Abbott Diabetes. R. Lane: None. Funding Eli-Lilly (37724)